Understanding Your HER2-Negative Diagnosis

Hearing the word “negative” in a medical diagnosis can feel like a relief, but in the world of breast cancer, it is not a description of your prognosis or how “serious” the cancer is ^[1]. Instead, HER2-negative is a technical classification that describes what is not driving your cancer’s growth ^[2].

Specifically, it means your cancer cells do not have high levels of a protein called HER2 (human epidermal growth factor receptor 2), which can cause cells to grow and divide more quickly ^[3]. Knowing your HER2 status is one of the most important first steps after diagnosis because it tells your care team which “tools” in their medical toolkit will be most effective for you—and which ones won’t be ^[4].

One Category, Two Very Different Diseases

“HER2-negative” is not a single disease. It is a broad umbrella that covers about 80% to 85% of all breast cancer cases ^[5][6]. Within this category, doctors look for two other markers: the Estrogen Receptor (ER) and the Progesterone Receptor (PR) ^[1].

Based on these results, HER2-negative breast cancer splits into two major subtypes:

1. Hormone Receptor-Positive (HR+/HER2-): This is the most common form of breast cancer, accounting for roughly 65% to 70% of all cases ^[5][7]. These cancers use hormones (estrogen or progesterone) to grow. Because they are fueled by hormones, they can often be treated with endocrine therapy (hormone therapy), which works by blocking these hormones or lowering their levels in the body ^[4].
2. Triple-Negative Breast Cancer (TNBC): This subtype makes up about 15% to 20% of cases ^[6][7]. It is called “triple-negative” because it lacks all three major markers: ER, PR, and HER2 ^[8]. Because TNBC isn’t fueled by hormones or the HER2 protein, standard hormone therapies do not work against it. Instead, treatment usually focuses on chemotherapy, surgery, radiation, and in some cases, immunotherapy or other targeted treatments ^[9]. (Note that while conventional HER2-targeted therapy is not used for HER2-0 disease, TNBC that is HER2-low or HER2-ultralow may qualify for specific antibody-drug conjugates in selected metastatic settings).

Understanding the HER2 Test Results

To determine your status, a pathologist looks at your tumor tissue under a microscope using a test called IHC (Immunohistochemistry) ^[10]. This test assigns a score from 0 to 3+ based on how much HER2 protein is visible on the surface of the cancer cells ^[3]:

• IHC 0 or 1+: These are considered HER2-negative ^[2].
• IHC 2+: This is considered “equivocal” (uncertain). If you receive this score, the lab will run a second, more detailed test called FISH or ISH (In Situ Hybridization) to look at the genes inside the cells ^[10]. If the FISH test is negative, the cancer is classified as HER2-negative ^[2].
• IHC 3+: This is HER2-positive.

The “HER2-Low” Distinction

Recently, researchers have found that even among “negative” results, there is a spectrum. You may hear your doctor use the term HER2-low if your IHC score is 1+ or if it is 2+ with a negative FISH test ^[11]. While still technically in the HER2-negative category, being “HER2-low” (or HER2-ultralow) may open up additional treatment options, particularly if the cancer is advanced or metastatic, depending on the exact drug, stage, prior therapy, and jurisdiction ^[12].

Processing Your Diagnosis

It is normal to feel overwhelmed or confused by these terms. Many patients find the word “negative” misleading, fearing it means they have fewer treatment options or a worse outlook. In reality, being HER2-negative simply means your cancer has a different biological “signature” than HER2-positive cancer ^[1].

Your subtype is just one piece of a larger puzzle. Your doctor will also consider the grade (how aggressive the cells look), the stage (how far it has spread), and your overall health to create a personalized plan ^[13]. While the category is broad, the treatment you receive will be highly specific to the unique characteristics of your tumor ^[14].